Enterovirus type 71 neutralizing antibodies in the serum of macaque monkeys immunized with EV71 virus-like particles

Vaccine

Volumn 30, Issue 7, 2012, Pages 1305-1312

  Lin, Yu Li ^a   Yu, Chun I ^b   Hu, Yu Chen ^c   Tsai, Tze Jiun ^b   Kuo, Yin Chieh ^d   Chi, Wei Kuang ^d   Lin, Ae Ning ^d   Chiang, Bor Luen ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^d DEVELOPMENT CENTER FOR BIOTECHNOLOGY   (Taiwan)

Author keywords

Enterovirus; Immunity; Vaccine; Virus like particle

Indexed keywords

ALUMINUM HYDROXIDE; ENTEROVIRUS 71 VACCINE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS LIKE PARTICLE VACCINE;

ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; ENTEROVIRUS 71; ENTEROVIRUS INFECTION; ENZYME LINKED IMMUNOSPOT ASSAY; HUMORAL IMMUNITY; IMMUNOGENICITY; MACACA; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; VIRION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CHILD, PRESCHOOL; ENTEROVIRUS A, HUMAN; ENTEROVIRUS INFECTIONS; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNOLOGIC MEMORY; MACACA; VACCINATION; VACCINES, INACTIVATED; VACCINES, VIRUS-LIKE PARTICLE; VIRAL VACCINES;

EID: 84862786637     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.12.081     Document Type: Article

References (35)

1. McMinn P.C. An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol Rev 2002, 26(March (1)):91-107.
2. Brown B.A., Oberste M.S., Alexander J.P., Kennett M.L., Pallansch M.A. Molecular epidemiology and evolution of enterovirus 71 strains isolated from 1970 to 1998. J Virol 1999, 73(December (12)):9969-9975.
3. Brown B.A., Pallansch M.A. Complete nucleotide sequence of enterovirus 71 is distinct from poliovirus. Virus Res 1995, 39(December (2-3)):195-205.
4. Toyoda H., Nicklin M.J., Murray M.G., Anderson C.W., Dunn J.J., Studier F.W., et al. A second virus-encoded proteinase involved in proteolytic processing of poliovirus polyprotein. Cell 1986, 45(June (5)):761-770.
5. Ypma-Wong M.F., Dewalt P.G., Johnson V.H., Lamb J.G., Semler B.L. Protein 3CD is the major poliovirus proteinase responsible for cleavage of the P1 capsid precursor. Virology 1988, 166(September (1)):265-270.
6. Tee K.K., Lam T.T., Chan Y.F., Bible J.M., Kamarulzaman A., Tong C.Y. Evolutionary genetics of human enterovirus 71: origin, population dynamics, natural selection, and seasonal periodicity of the VP1 gene. J Virol 2010, 84(April (7)):3339-3350.
7. Cardosa M.J., Perera D., Brown B.A., Cheon D., Chan H.M., Chan K.P., et al. Molecular epidemiology of human enterovirus 71 strains and recent outbreaks in the Asia-Pacific region: comparative analysis of the VP1 and VP4 genes. Emerg Infect Dis 2003, 9(April (4)):461-468.
8. Qiu J. Enterovirus 71 infection: a new threat to global public health?. Lancet Neurol 2008, 7(October (10)):868-869.
9. Wang S.M., Lei H.Y., Yu C.K., Wang J.R., Su I.J., Liu C.C. Acute chemokine response in the blood and cerebrospinal fluid of children with enterovirus 71-associated brainstem encephalitis. J Infect Dis 2008, 198(October (7)):1002-1006.
10. Fowlkes A.L., Honarmand S., Glaser C., Yagi S., Schnurr D., Oberste M.S., et al. Enterovirus-associated encephalitis in the California encephalitis project, 1998-2005. J Infect Dis 2008, 198(December (11)):1685-1691.
11. Lin T.Y., Twu S.J., Ho M.S., Chang L.Y., Lee C.Y. Enterovirus 71 outbreaks, Taiwan: occurrence and recognition. Emerg Infect Dis 2003, 9(March (3)):291-293.
12. Chang L.Y., Tsao K.C., Hsia S.H., Shih S.R., Huang C.G., Chan W.K., et al. Transmission and clinical features of enterovirus 71 infections in household contacts in Taiwan. JAMA 2004, 291(January (2)):222-227.
13. Wang S.M., Lei H.Y., Huang K.J., Wu J.M., Wang J.R., Yu C.K., et al. Pathogenesis of enterovirus 71 brainstem encephalitis in pediatric patients: roles of cytokines and cellular immune activation in patients with pulmonary edema. J Infect Dis 2003, 188(August (4)):564-570.
14. Wu C.N., Lin Y.C., Fann C., Liao N.S., Shih S.R., Ho M.S. Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine 2001, 20(December (5-6)):895-904.
15. Shih S.R., Li Y.S., Chiou C.C., Suen P.C., Lin T.Y., Chang L.Y., et al. Expression of capsid [correction of caspid] protein VP1 for use as antigen for the diagnosis of enterovirus 71 infection. J Med Virol 2000, 61(June (2)):228-234.
16. Chen H.L., Huang J.Y., Chu T.W., Tsai T.C., Hung C.M., Lin C.C., et al. Expression of VP1 protein in the milk of transgenic mice: a potential oral vaccine protects against enterovirus 71 infection. Vaccine 2008, 26(June (23)):2882-2889.
17. Chen H.F., Chang M.H., Chiang B.L., Jeng S.T. Oral immunization of mice using transgenic tomato fruit expressing VP1 protein from enterovirus 71. Vaccine 2006, 24(April (15)):2944-2951.
18. Ong KC, Devi S, Cardosa MJ, Wong KT. Formaldehyde-inactivated whole-virus vaccine protects a murine model of enterovirus 71 encephalomyelitis against disease. J Virol 2010;84(January (1)):661-5.
19. Chung Y.C., Huang J.H., Lai C.W., Sheng H.C., Shih S.R., Ho M.S., et al. Expression, purification and characterization of enterovirus-71 virus-like particles. World J Gastroenterol 2006, 12(February (6)):921-927.
20. Chung Y.C., Ho M.S., Wu J.C., Chen W.J., Huang J.H., Chou S.T., et al. Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine 2008, 26(March (15)):1855-1862.
21. Lin Y.C., Wu C.N., Shih S.R., Ho M.S. Characterization of a Vero cell-adapted virulent strain of enterovirus 71 suitable for use as a vaccine candidate. Vaccine 2002, 20(June (19-20)):2485-2493.
22. Ramqvist T., Andreasson K., Dalianis T. Vaccination, immune and gene therapy based on virus-like particles against viral infections and cancer. Expert Opin Biol Ther 2007, 7(July (7)):997-1007.
23. Szarewski A. HPV vaccine: cervarix. Expert Opin Biol Ther 2010, 10(March (3):):477-487.
24. Buonaguro F.M., Tornesello M.L., Buonaguro L. Virus-like particle vaccines and adjuvants: the HPV paradigm. Expert Rev Vaccines 2009, 8(October (10)):1379-1398.
25. Young K.R., McBurney S.P., Karkhanis L.U., Ross T.M. Virus-like particles: designing an effective AIDS vaccine. Methods 2006, 40(September (1)):98-117.
26. Shi L., Sings H.L., Bryan J.T., Wang B., Wang Y., Mach H., et al. GARDASIL: prophylactic human papillomavirus vaccine development - from bench top to bed-side. Clin Pharmacol Ther 2007, 81(February (2)):259-264.
27. Meng T., Kolpe A.B., Kiener T.K., Chow V.T., Kwang J. Display of VP1 on the surface of baculovirus and its immunogenicity against heterologous human enterovirus 71 strains in mice. PLoS One 2011, 6(7):e21757.
28. Foo D.G., Alonso S., Phoon M.C., Ramachandran N.P., Chow V.T., Poh C.L. Identification of neutralizing linear epitopes from the VP1 capsid protein of enterovirus 71 using synthetic peptides. Virus Res 2007, 125(April (1)):61-68.
29. Rajagopal D., Paturel C., Morel Y., Uematsu S., Akira S., Diebold S.S. Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists. Blood 2010, 115(March (10)):1949-1957.
30. Tee K.K., Lam T.T., Chan Y.F., Bible J.M., Kamarulzaman A., Tong C.Y., et al. Evolutionary genetics of human enterovirus 71: origin, population dynamics, natural selection, and seasonal periodicity of the VP1 gene. J Virol 2010, 84(April (7)):3339-3350.
31. Solomon T., Lewthwaite P., Perera D., Cardosa M.J., McMinn P., Ooi M.H. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis 2010, 10(November (11)):778-790.
32. Smith J.F., Brownlow M., Brown M., Kowalski R., Esser M.T., Ruiz W. Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions. Hum Vaccin 2007, 3(July-August (4)):109-115.
33. Roden R.B., Hubbert N.L., Kirnbauer R., Christensen N.D., Lowy D.R., Schiller J.T. Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition. J Virol 1996, 70(May (5)):3298-3301.
34. Giroglou T., Sapp M., Lane C., Fligge C., Christensen N.D., Streeck R.E., et al. Immunological analyses of human papillomavirus capsids. Vaccine 2001, 19(February (13-14)):1783-1793.
35. Combita A.L., Bravo M.M., Touze A., Orozco O., Coursaget P. Serologic response to human oncogenic papillomavirus types 16, 18, 31, 33, 39, 58 and 59 virus-like particles in colombian women with invasive cervical cancer. Int J Cancer 2002, 97(February (6)):796-803.